Chen Lin, Assistant Professor at Duke Cancer Institute, shared a post on X:
“The search for optimal ven dosing continues!
oral of ‘7+7’ (7d aza/7d ven) vs. ‘standard’ HMA/VEN in AML:
– Similar CRc and OS
– Decreased 8-wk mortality with 7+7 (6% vs. 17%)
– Less platelet transfusions
Much variation even in ‘standard’ HMA/VEN. What were rates of relapse?”
Source: Chen Lin/X